Can Bikeren Pronol Tablets (Bituvi) be effective in treating HIV infection?

Biktarvy tablets (Biktarvy) is an oral fixed-dose combination antiretroviral drug, consisting of bictegravir (Bictegravir), tenofum fumarate It consists of three active ingredients: alafenacetate fuvir (TAF) and emtricitabine (Emtricitabine). Its mechanism inhibits HIV integrase and reverse transcriptase activities, blocking viral replication and integration into host DNA, thereby controlling the number of viruses and delaying disease progression. Due to its strong efficacy and good tolerability, Biktarvy is recommended as an important option for the initial treatment and long-term maintenance treatment of HIV infection.

Multiple clinical studies have shown that Biktarvy has highly effective viral suppression in HIV infected patients. In treatment-naïve patients, the proportion of plasmaHIV RNA reduced to undetectable levels within 48 weeks of taking Biktarvy can exceed 90%, significantly increasing CD4+ T cell counts and improving immune function. The drug has shown stable efficacy in patients of different age groups, genders and patients with underlying diseases, providing reliable guarantee for long-term virus control.

BiktarvyIt has a high resistance barrier, and fewer viral resistance mutations occur during long-term treatment, reducing the risk of treatment failure. At the same time, the compound drug can be taken orally once a day, simplifying the medication regimen and improving patient compliance. Side effects are relatively mild, with mild gastrointestinal discomfort, headache or rash being common. Most are tolerable and do not affect long-term medication plans. The good safety profile and resistance barrier make it an ideal maintenance treatment drug for HIVinfected patients.

In actual clinical application, Biktarvy is suitable for HIV-1 infected patients, including those who are new to treatment and those who have received other antiviral regimens. Liver and kidney function evaluation must be performed before use, and plasma HIV RNA and CD4+ T cell levels must be monitored regularly to evaluate efficacy and safety. Overall, Biktarvy can effectively inhibit HIV replication, restore immune function, and reduce the risk of disease progression, and is widely recognized clinically as HIVCore drugs in the management of infection and AIDS.

Reference materials:https://www.drugs.com/